47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01

M. Droz Dit Busset, W. L. Shaib,K. Mody, N. Personeni,N. Damjanov,W. P. Harris, F. Bergamo,G. Brandi,G. Masi,T. R. Halfdanarson, V. Tam, L. W. Goff,J. Knox,A. Hollebecque,T. Macarulla Mercade, F. Cantero, M. Saulay, S. Braun, M. Javle,M. Borad

Annals of Oncology(2021)

引用 12|浏览5
暂无评分
关键词
intrahepatic cholangiocarcinoma,fgfr2 fusions/rearrangements,derazantinib
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要